Affordable Access

deepdyve-link
Publisher Website

Molecular profiling and molecular classification of endometrioid ovarian carcinomas.

Authors
  • Cybulska, Paulina1
  • Paula, Arnaud Da Cruz1
  • Tseng, Jill1
  • Leitao, Mario M Jr1
  • Bashashati, Ali2
  • Huntsman, David G3
  • Nazeran, Tayyebeh M4
  • Aghajanian, Carol5
  • Abu-Rustum, Nadeem R1
  • DeLair, Deborah F6
  • Shah, Sohrab P7
  • Weigelt, Britta8
  • 1 Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 2 Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. , (Canada)
  • 3 Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. , (Canada)
  • 4 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. , (Canada)
  • 5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 6 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 7 Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada; Department of Epidemiology & Biostatistics, Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. , (Canada)
  • 8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: [email protected]
Type
Published Article
Journal
Gynecologic Oncology
Publisher
Elsevier
Publication Date
Sep 01, 2019
Volume
154
Issue
3
Pages
516–523
Identifiers
DOI: 10.1016/j.ygyno.2019.07.012
PMID: 31340883
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Endometrioid ovarian carcinomas (EOCs) comprise 5-10% of all ovarian cancers and commonly co-occur with synchronous endometrioid endometrial cancer (EEC). We sought to examine the molecular characteristics of pure EOCs in patients without concomitant EEC. EOCs and matched normal samples were subjected to massively parallel sequencing targeting 341-468 cancer-related genes (n = 8) or whole-genome sequencing (n = 28). Mutational frequencies of EOCs were compared to those of high-grade serous ovarian cancers (HGSOCs; n = 224) and EECs (n = 186) from The Cancer Genome Atlas, and synchronous EOCs (n = 23). EOCs were heterogeneous, frequently harboring KRAS, PIK3CA, PTEN, CTNNB1, ARID1A and TP53 mutations. EOCs were distinct from HGSOCs at the mutational level, less frequently harboring TP53 but more frequently displaying KRAS, PIK3CA, PIK3R1, PTEN and CTNNB1 mutations. Compared to synchronous EOCs and pure EECs, pure EOCs less frequently harbored PTEN, PIK3R1 and ARID1A mutations. Akin to EECs, EOCs could be stratified into the four molecular subtypes: 3% POLE (ultramutated), 19% MSI (hypermutated), 17% copy-number high (serous-like) and 61% copy-number low (endometrioid). In addition to microsatellite instability, a subset of EOCs harbored potentially targetable mutations, including AKT1 and ERBB2 hotspot mutations. EOCs of MSI (hypermutated) subtype uniformly displayed a good outcome. EOCs are heterogeneous at the genomic level and harbor targetable genetic alterations. Despite the similarities in the repertoire of somatic mutations between pure EOCs, synchronous EOCs and EECs, the frequencies of mutations affecting known driver genes differ. Further studies are required to define the impact of the molecular subtypes on the outcome and treatment of EOC patients. Copyright © 2019 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times